Five-year Evolut Low Risk results for valve-only procedures
A 2026 analysis of the Evolut Low Risk trial found death or disabling stroke at five years was similar after TAVR and surgery in people having only the valve replaced (15.5% versus 14.6%). New pacemakers were more common after TAVR (27.3% versus 8.9%).
What this could change in a conversation with your surgeon: For lower-risk patients, TAVR and surgery look similar at five years, but pacemaker risk is a real tradeoff to discuss.
Sources: Ann Thorac Surg (DOI)
